









Markets
/
Stocks
/
nasdaq-silo
/

Silo Pharma Inc

SILO

0.500USD

-0.020-3.79%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

4.33MMarket Cap

LossP/E TTM



Silo Pharma Inc

0.500

-0.020-3.79%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Silo Pharma Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Silo Pharma Inc's Score

Industry at a Glance

Industry Ranking

126 / 159

Overall Ranking

416 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Silo Pharma Inc Highlights

StrengthsRisks

Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).

Growing

The company is in a growing phase, with the latest annual income totaling USD 72.10K.

Overvalued

The company’s latest PE is -0.49, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 406.81K shares, increasing 11.50% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 16.33K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.79.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.49, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 18.02K, representing a year-over-year increase of 0.00%, while its net profit experienced a year-over-year increase of 29.25%.

Score

Industry at a Glance

Previous score

6.49

Change



Financials

8.96

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.81

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.99

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Silo Pharma Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.19, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -0.49, which is -23.55% below the recent high of -0.37 and -501.68% above the recent low of -2.94.

Score

Industry at a Glance

Previous score

8.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 126/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.77.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 6.46, which is lower than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 0.68 and the support level at 0.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.41

Change

1.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.010

Sell

RSI(14)

36.133

Neutral

STOCH(KDJ)(9,3,3)

14.581

Sell

ATR(14)

0.054

Low Volatility

CCI(14)

-143.171

Sell

Williams %R

55.082

Sell

TRIX(12,20)

-1.005

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.531

Sell

MA10

0.547

Sell

MA20

0.579

Sell

MA50

0.645

Sell

MA100

0.644

Sell

MA200

0.890

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 3.05%, representing a quarter-over-quarter decrease of 77.25%. The largest institutional shareholder is The Vanguard, holding a total of 16.33K shares, representing 0.12% of shares outstanding, with 66.34% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

SEG Opportunity Fund LLC

952.38K

Weisblum (Eric)

197.93K

AdvisorShares Investments, LLC

184.24K

+48.30%

Two Sigma Investments, LP

43.22K

Geode Capital Management, L.L.C.

39.31K

-11.64%

Ursa Fund Management, LLC

37.50K

Citadel Advisors LLC

28.16K

+36.11%

XTX Markets LLC

26.82K

The Vanguard Group, Inc.

Star Investors

16.33K

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.69, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.63. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.